Alteogen (196170 KS): Modified License Agreement For Major Platform Technology Is A Hard Catalyst
Alteogen modifies license agreement with Merck, granting exclusive global rights for ALT-B4 for pembrolizumab for an upfront payment of $20M and...
565 Views
CX Daily: China’s Three-Year Stock Slump Resists Policy Prescriptions for Rebound
Stocks / Cover Story: China’s three-year stock slump resists policy prescriptions for rebound Chinese investors began 2023 full of optimism that...
30 Views
Orion Corp: Concerns About Diversification into LegoChem Bioscience
Orion Corp's investment in LegoChem Bio raises concerns about diversification into risky biotech business. Investors would rather have Orion Corp...
321 Views
QuantumPharm (XtalPi) Pre-IPO Tearsheet
QuantumPharm (QUP HK) is looking to raise US$200m in its upcoming Hong Kong IPO. The bookrunner on the deal is Citic Securities.
508 Views
WuXi XDC IPO Valuation Analysis: Premium Multiples Reflect 100%+ Top-Line Growth
WuXi XDC set terms for an upcoming IPO in Hong Kong. The company plans to raise ~$470M, and the IPO price range implies a market cap of ~$3B at the...
596 Views